Research & Regulatory News

Semaglutide in Obesity-Related Heart Failure

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Kosiborod and colleagues published semaglutide in patients with heart failure with preserved ejection fraction and obesity in the New England Journal of Medicine in September 2023, followed by a pooled analysis of the STEP-HFpEF programme in the Lancet in April 2024.

Key facts

Kosiborod 2023
NEJM, 21 September (PMID 37622681)
Butler 2024
Lancet, pooled analysis (PMID 38599221)
Population
Obesity-related HFpEF
Design
Randomised, placebo-controlled
Contrast
Tirzepatide HFpEF data is observational
Under regulatory review
Reported for this indication

Why HFpEF is a distinct target

Heart failure with preserved ejection fraction is heterogeneous, and one recognised phenotype is closely tied to obesity and metabolic disease. That association makes substantial weight reduction a mechanistic hypothesis in this population specifically, rather than an opportunistic extension of an obesity drug into cardiology.

Why randomised evidence matters more here than usual

HFpEF has resisted treatment for decades, and the field carries a long record of observational associations that randomised trials failed to confirm. In that context a randomised placebo-controlled trial is not merely preferable. It is the only design the specialty is likely to accept, given how many promising associations have not survived one.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What the pooled analysis adds

Butler and colleagues pooled the STEP-HFpEF programme in the Lancet in April 2024. Pooling related randomised trials increases precision and allows subgroup questions that individual trials are underpowered for, while keeping randomisation intact, the same advantage the gallbladder meta-analysis exploits.

How this sits beside the tirzepatide work

This site separately covers tirzepatide in HFpEF, which was studied by target trial emulation on retrospective cohort data. That design removes analytical biases but cannot balance unmeasured factors. STEP-HFpEF is randomised. Both concern HFpEF and they are not the same grade of evidence, which is a distinction usually lost when results are listed together.

What a regulatory filing does and does not mean

Semaglutide has been reported as under review for this indication. A submission means a sponsor considers the evidence sufficient to ask; it is not an approval, and the assessment is what determines whether the indication is granted and on what terms.

The boundary

Semaglutide is a licensed medicine and these were registered trials conducted under clinical supervision. Nothing supplied on this site is semaglutide, is related to it, or is an alternative to any treatment for heart failure.

Frequently asked questions

Why study a weight-loss drug in heart failure?

One recognised HFpEF phenotype is closely associated with obesity and metabolic disease, which makes substantial weight reduction a mechanistic hypothesis.

How does this differ from the tirzepatide HFpEF data?

STEP-HFpEF is randomised and placebo-controlled. The tirzepatide work used target trial emulation on retrospective cohort data, a weaker design.

Is it approved for heart failure?

It has been reported as under regulatory review for the indication. A submission is a request for assessment, not an approval.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Research & Regulatory News articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.